Cargando…
The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy, with an overall 5-year survival of only 47%. As the development of novel targeted therapies is drastically necessary in order to improve patient survival, current EOC clinical trials have heavily focused on immunotherapeutic...
Autores principales: | James, Nicole E., Woodman, Morgan, DiSilvestro, Paul A., Ribeiro, Jennifer R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466102/ https://www.ncbi.nlm.nih.gov/pubmed/32756436 http://dx.doi.org/10.3390/cancers12082150 |
Ejemplares similares
-
Septin-2 is overexpressed in epithelial ovarian cancer and mediates proliferation via regulation of cellular metabolic proteins
por: James, Nicole E., et al.
Publicado: (2019) -
Human Epididymis Protein 4 Promotes Events Associated with Metastatic Ovarian Cancer via Regulation of the Extracelluar Matrix
por: Ribeiro, Jennifer R., et al.
Publicado: (2018) -
COL1A1-PDGFB fusion uterine sarcoma and its response to Imatinib therapy
por: Grindstaff, Samuel L., et al.
Publicado: (2020) -
Inhibition of DUSP6 sensitizes ovarian cancer cells to chemotherapeutic agents via regulation of ERK signaling response genes
por: James, Nicole E., et al.
Publicado: (2019) -
COL1A1-PDGFB fusion uterine fibrosarcoma: A case report with treatment implication
por: Grindstaff, Samuel L., et al.
Publicado: (2019)